Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
1.400
+0.030 (2.19%)
Mar 6, 2026, 2:41 PM EST - Market open
Jasper Therapeutics Employees
Jasper Therapeutics had 64 employees as of December 31, 2024. The number of employees increased by 19 or 42.22% compared to the previous year.
Employees
64
Change (1Y)
19
Growth (1Y)
42.22%
Revenue / Employee
n/a
Profits / Employee
-$3,371,148
Market Cap
39.18M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64 | 19 | 42.22% |
| Dec 31, 2023 | 45 | 10 | 28.57% |
| Dec 31, 2022 | 35 | 10 | 40.00% |
| Dec 31, 2021 | 25 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 70 |
| Xilio Therapeutics | 64 |
| Palatin Technologies | 29 |
| Lisata Therapeutics | 26 |
| Veru Inc. | 20 |
| Atossa Therapeutics | 15 |
| Sensei Biotherapeutics | 15 |
| CervoMed | 15 |
JSPR News
- 9 days ago - Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference - GlobeNewsWire
- 2 months ago - Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria Transcript - Seeking Alpha
- 2 months ago - Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria - GlobeNewsWire
- 2 months ago - Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth - GlobeNewsWire
- 3 months ago - Jasper Therapeutics, Inc. (JSPR) Discusses Investigation Into BEACON Study Anomalies and Preliminary ETESIAN Asthma Data Transcript - Seeking Alpha
- 3 months ago - Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation - GlobeNewsWire
- 3 months ago - Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation - GlobeNewsWire
- 3 months ago - Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewsWire